- Health Canada has approved BeiGene Ltd BGNE Brukinsa (zanubrutinib) for the treatment of mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.
- This is the second approval for Brukinsa in Canada, following its initial approval in March for adult patients with Waldenström's macroglobulinemia (WM).
- The Health Canada approval is based on efficacy results from two trials that achieved an overall response rate of 84%.
- Price Action: BGNE shares are trading lower by 6.75% at 295.57 on the last check Monday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
